Mark's questions to Summit Therapeutics Inc (SMMT) leadership • Q1 2025
Question
Mark, on behalf of Salveen, asked about the bar for success for the upcoming HARMONi EGFR dataset, how closely it needs to mirror Chinese data, and the competitive profile needed to convince doctors to use ivonescimab versus RYBREVANT.
Answer
Dave Gancarz, an executive, stated that Summit will not set a specific numerical bar, focusing instead on the overall consistency of the global data package. Dr. H. Jack West, VP and Thoracic Oncology TA Head, added that there is a strong need for alternatives with different toxicity profiles, like ivonescimab, especially as other therapies move into the first-line setting.